...
首页> 外文期刊>Ocular immunology and inflammation >Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab
【24h】

Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab

机译:点状内脉络膜病或多焦脉络膜炎的长期结果,具有激活的脉络膜新生血管形成,用玻璃体玻璃纤维素管理

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after intravitreal bevacizumab treatment. Methods: Retrospective study of consecutive patients of PIC/MFC complicated with active CNV. Outcome measures included best-corrected visual acuity (BCVA), total number of intravitreal injections of bevacizumab and recurrence of CNV. Correlation analysis was performed to find the correlation of various clinical factors and final BCVA. Results: There were 23 eyes in 22 patients with a mean age of 33.22 years included in this study. The mean duration of follow-up was 6.48 years. Improvement of BCVA was noted through the first 3 years and at the final follow-up. BCVA at 1, 6, 12 months and recurrence of CNV were correlated with final BCVA. Conclusion: Most patients of PIC/MFC complicated with CNV managed with intravitreal bevacizumab had improved BCVA over 4 years.
机译:目的:在玻璃体内贝伐单抗治疗后评估点状内脉络膜病(PIC)或多焦脉络炎(MFC)中的活性脉络膜新生血管(CNV)的长期结果。 方法:对PIC / MFC复杂活性CNV的连续患者的回顾性研究。 结果措施包括最佳纠正的视力(BCVA),玻璃体内注射的总嗜纤维素射精和CNV的复发。 进行相关分析以找到各种临床因素和最终BCVA的相关性。 结果:22名患者中有23只眼睛,涉及该研究的平均年龄为33.22岁。 随访的平均持续时间为6.48年。 通过前3年和最后的后续行动指出了BCVA的改进。 BCVA在1,6,12个月和CNV的复发与最终BCVA相关。 结论:大多数PIC / MFC患者与玻璃体内贝伐单抗管理的CNV复杂的CNV有超过4年改善BCVA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号